Current and Future Immunomodulation Strategies to Restore Tolerance in Autoimmune Diseases

被引:31
作者
Bluestone, Jeffrey A. [1 ]
Bour-Jordan, Helene [1 ]
机构
[1] Univ Calif San Francisco, UCSF Diabet Ctr, San Francisco, CA 94143 USA
来源
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY | 2012年 / 4卷 / 11期
基金
美国国家卫生研究院;
关键词
REGULATORY T-CELLS; MYELIN BASIC-PROTEIN; INTRAVENOUS IMMUNOGLOBULIN THERAPY; ANTI-CD3; MONOCLONAL-ANTIBODY; ACTIVE RHEUMATOID-ARTHRITIS; BONE-MARROW-TRANSPLANTATION; ANTIGEN-SPECIFIC TOLERANCE; ALTERED PEPTIDE LIGAND; NONOBESE DIABETIC MICE; MULTIPLE-SCLEROSIS;
D O I
10.1101/cshperspect.a007542
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Autoimmune diseases reflect a breakdown in self-tolerance that results from defects in thymic deletion of potentially autoreactive T cells (central tolerance) and in T-cell intrinsic and extrinsic mechanisms that normally control potentially autoreactive T cells in the periphery (peripheral tolerance). The mechanisms leading to autoimmune diseases are multifactorial and depend on a complex combination of genetic, epigenetic, molecular, and cellular elements that result in pathogenic inflammatory responses in peripheral tissues driven by self-antigen-specific T cells. In this article, we describe the different checkpoints of tolerance that are defective in autoimmune diseases as well as specific events in the autoimmune response which represent therapeutic opportunities to restore long-term tolerance in autoimmune diseases. We present evidence for the role of different pathways in animal models and the therapeutic strategies targeting these pathways in clinical trials in autoimmune diseases.
引用
收藏
页数:23
相关论文
共 198 条
  • [111] Autoimmunity risk alleles in costimulation pathways
    Maier, Lisa M.
    Hafler, David A.
    [J]. IMMUNOLOGICAL REVIEWS, 2009, 229 : 322 - 336
  • [112] Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720
    Maki, T
    Gottschalk, R
    Ogawa, N
    Monaco, AP
    [J]. TRANSPLANTATION, 2005, 79 (09) : 1051 - 1055
  • [113] CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice:: implications for the nonredundant function of IL-2
    Malek, TR
    Yu, AX
    Vincek, V
    Scibelli, P
    Kong, L
    [J]. IMMUNITY, 2002, 17 (02) : 167 - 178
  • [114] Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists
    Mandala, S
    Hajdu, R
    Bergstrom, J
    Quackenbush, E
    Xie, J
    Milligan, J
    Thornton, R
    Shei, GJ
    Card, D
    Keohane, C
    Rosenbach, M
    Hale, J
    Lynch, CL
    Rupprecht, K
    Parsons, W
    Rosen, H
    [J]. SCIENCE, 2002, 296 (5566) : 346 - 349
  • [115] Oral tolerance to copolymer 1 in myelin basic protein (MBP) TCR transgenic mice: cross-reactivity with MBP-specific TCR and differential induction of anti-inflammatory cytokines
    Maron, R
    Slavin, AJ
    Hoffmann, E
    Komagata, Y
    Weiner, HL
    [J]. INTERNATIONAL IMMUNOLOGY, 2002, 14 (02) : 131 - 138
  • [116] Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice
    Masteller, EL
    Warner, MR
    Tang, QZ
    Tarbell, KV
    McDevitt, H
    Bluestone, JA
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (05) : 3053 - 3059
  • [117] Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
    Matloubian, M
    Lo, CG
    Cinamon, G
    Lesneski, MJ
    Xu, Y
    Brinkmann, V
    Allende, ML
    Proia, RL
    Cyster, JG
    [J]. NATURE, 2004, 427 (6972) : 355 - 360
  • [118] Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes
    McClymont, Stephanie A.
    Putnam, Amy L.
    Lee, Michael R.
    Esensten, Jonathan H.
    Liu, Weihong
    Hulme, Maigan A.
    Hoffmueller, Ulrich
    Baron, Udo
    Olek, Sven
    Bluestone, Jeffrey A.
    Brusko, Todd M.
    [J]. JOURNAL OF IMMUNOLOGY, 2011, 186 (07) : 3918 - 3926
  • [119] Multiple sclerosis: a complicated picture of autoimmunity
    McFarland, Henry F.
    Martin, Roland
    [J]. NATURE IMMUNOLOGY, 2007, 8 (09) : 913 - 919
  • [120] The Efficacy and Safety of Abatacept in Patients With Non-Life-Threatening Manifestations of Systemic Lupus Erythematosus Results of a Twelve-Month, Multicenter, Exploratory, Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial
    Merrill, J. T.
    Burgos-Vargas, R.
    Westhovens, R.
    Chalmers, A.
    D'Cruz, D.
    Wallace, D. J.
    Bae, S. C.
    Sigal, L.
    Becker, J. -C.
    Kelly, S.
    Raghupathi, K.
    Li, T.
    Peng, Y.
    Kinaszczuk, M.
    Nash, P.
    [J]. ARTHRITIS AND RHEUMATISM, 2010, 62 (10): : 3077 - 3087